Current stock page

Financial Data

ASND Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

ASNDAscendis Pharma A/S

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 9/10
$275.39+$8.32 (+3.12%)

Latest quote

  • Momentum
    75
  • Value
    66
  • Quality
    71
  • Risk resilience
    72
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$367.46M$344.9M$250.66M$245.18M$213.63M$158.05M$100.95M$173.92M
Gross Profit$335.16M$312.61M$229.03M$217.98M$191.28M$126.6M$83.44M$159.89M
Operating Income$123.84M$63.43M$25.22M$9.8M$11M-$52.95M-$104.21M$383K
Net Income$73.53M$210.4M$639.69M-$33.25M-$60.99M-$38.86M-$94.63M-$38.47M
EPS$1.11$3.27$10.37-$0.54-$1-$0.64-$1.58-$0.64
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow$184.7M$286.35M-$7.85M$70.67M$2.15M-$7.34M-$14.31M-$87.18M
Capital Expenditure-$2.63M-$3.24M-$7.84M-$3.3M-$53K-$4.34M-$703K-$383K
Free Cash Flow$182.07M$283.11M-$15.69M$67.37M$2.1M-$11.68M-$15.02M-$87.56M
Net Cash Provided By Operating Activities$184.7M$286.35M-$7.85M$70.67M$2.15M-$7.34M-$14.31M-$87.18M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$2.47B$2.29B$2.01B$1.3B$1.15B$1.09B$1.06B$1.18B
Total Debt$455.38M$449.89M$897.6M$871.41M$813.65M$792.53M$847.27M$856.62M
Cash And Cash Equivalents$980.69M$811.92M$573.42M$615.78M$539.09M$494.05M$517.92M$559.54M
Total Liabilities$942.42M$849.18M$1.52B$1.46B$1.33B$1.28B$1.25B$1.29B
Total Stockholders Equity$1.53B$1.44B$488.48M-$162.75M-$174.08M-$187.57M-$189.81M-$105.71M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio19.2719.326.73—————
P/B ratio11.2510.1627.72—————
P/S ratio14.2———————
Debt To Equity0.30.311.84—————
Free Cash Flow Yield3.01%2.31%0.31%0.37%-1.07%———
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio19.2719.326.73—————
P/B ratio11.2510.1627.72—————
P/S ratio14.2———————
Return On Equity58.35%52.64%103.71%—————
Debt To Equity0.30.311.84—————

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe17.57x
Pb10.76x
Revenue Growth Yoy72.01%
EPS Growth Yoy211.00%
Gross Margin90.61%
Operating Margin18.40%
ROE108.33%
ROIC11.22%
Debt To Equity0.3
FCF Yield3.16%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$275.39
Volume826,098
RSI (14)74.7
MACD7.75
MACD signal5.5
MACD histogram2.26
ADX (14)37.86
SMA (50)$242.67
SMA (200)$239.85
ATR (14)$7.14
Historical volatility (annualized)22.30%
Volume (20-day average)701,749

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score72/100
Beta0.4
Annual volatility38.55%
Max Drawdown-19.66%
Sharpe Ratio0.84
VaR (95%, 1-day)-3.58%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

ASND Financial Data FAQ

What is Ascendis Pharma A/S's revenue?

Ascendis Pharma A/S's revenue is one of the core financial data points for ASND. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Ascendis Pharma A/S's revenue growing?

Revenue growth shows whether Ascendis Pharma A/S is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is ASND's EPS?

ASND's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Ascendis Pharma A/S's net income?

Ascendis Pharma A/S's net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Ascendis Pharma A/S generate?

Free cash flow shows how much cash Ascendis Pharma A/S generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Ascendis Pharma A/S have?

Cash and debt help frame ASND's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.